Movano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision
Rhea-AI Summary
Movano Health submitted exemplary SpO2 clinical trial results to the FDA as part of its 510(k) filing for the Evie Med Ring pulse oximeter. The Company aims to disrupt the wearables industry and unlock partnership opportunities with potential FDA clearance expected in July 2024. The recent clinical trial results demonstrated high accuracy across skin tones, surpassing FDA guidelines and outperforming hospital-grade reference pulse oximeters. Movano Health closed a $24 million private placement, received a strategic investment from a major medical device company, and signed collaboration agreements to advance its wearable medical device solutions.
Positive
Movano Health achieved high accuracy in its SpO2 clinical trial results, exceeding FDA guidelines and outperforming hospital-grade reference pulse oximeters, showcasing the effectiveness of the Evie Med Ring pulse oximeter.
The Company closed a $24 million private placement, received a strategic investment from a major medical device company, and signed collaboration agreements, strengthening its financial position and paving the way for future partnerships and technological advancements.
Negative
The FDA clearance decision for the Evie Med Ring pulse oximeter is pending until July 2024, creating a level of uncertainty for Movano Health's future commercialization plans and potential business growth until a decision is reached.
While the recent clinical trial results were promising, any future discrepancies or delays in FDA clearance could impact Movano Health's market positioning and partnerships within the wearables and healthcare industries.
News Market Reaction – MOVE
In the trading session that priced this news, MOVE declined 1.28%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Unlocking business-to-business opportunities with Evie Med, Movano Health's ring pulse oximeter, remains a key priority for the Company.
"From the outset, our vision has been to develop a wearable that fits with any lifestyle and is cleared by the FDA as a medical device," said John Mastrototaro, CEO of Movano Health. "The exemplary results of our latest study are a critical component of our FDA filing and lay the groundwork to fulfilling all aspects of that goal."
In January 2024, Movano Health completed a second hypoxia trial with the University of
During the trial, each subject wore four Evie Med Rings. The four Evie Med Rings achieved a pooled root mean square error (RMSE) of
Movano Health also recently closed a
The net proceeds of the private placement are expected to be used for general corporate purposes and working capital, including accelerating the development of Movano Health's proprietary technologies and wearable medical device solutions for healthcare enterprises, including pharmaceutical, medical device and health insurers.
About The Evie Med Ring
The Evie Med Ring combines medical device and wellness metrics to give a full picture of one's health. In addition to pulse oximeter medical data (SpO2 and pulse), these wellness metrics will be provided:
- Activity: log a workout, active minutes, steps, distance traveled, heart rate, and calories burned
- Sleep: start time, stop time, duration, and cycles (awake, light, deep, and rapid eye movement (REM)), resting heart rate average, oxygenation maximum, heart rate variability, respiration rate, skin temperature variability average)
- Women's health tracking: menstrual cycle and ovulation, mood, energy, and symptom tracking
- Goal setting (sleep, active minutes, steps, mood and symptoms, workout sessions)
- Daily Summary graphic (activity, calories, steps, and sleep, mood and energy logging)
This data is delivered through a companion mobile app which aims to simplify how data is presented, moving away from complex graphs and charts, and turning biometric data into actionable insights that will help consumers make manageable lifestyle changes and patients and their health care providers to take a more proactive approach to managing and treating chronic disease in healthcare and home environments.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the closing of the private placement transaction; plans with respect to commercial launch of the Evie Ring; planned cost-cutting initiatives; anticipated FDA clearance for the Evie Ring and other products in development; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-submits-exemplary-sp02-clinical-trial-results-in-key-step-towards-fda-510k-clearance-decision-302140861.html
SOURCE Movano